Hulio

Biocon Biologics Hulio launch, Hulio biosimilar Humira US, Biocon Biologics pricing strategy, Hulio patient-friendly device, Hulio market share US, Biocon Biologics Viatris acquisition, Hulio biosimilar approval FDA,

Biocon Biologicsā€™ CEO reveals pricing strategy and device design for Hulio, its Humira biosimilar, in the US market

Anika Sharma

The competition in the biosimilar arena targeting AbbVie’s blockbuster drug Humira, also known as adalimumab, is heating up. However, for ...